The U.S. FDA has granted priority approval for a first-line maintenance therapy combining Jazz Pharmaceuticals' Zepzelca (lurbinectedin) with Roche's Tecentriq (atezolizumab), or Tecentriq plus hyaluronidase, to treat extensive-stage small-cell lung cancer (SCLC). This approval, based on the phase III Imforte study, demonstrated significant reductions in disease progression and mortality risk compared to Tecentriq alone. The combination represents the first approved first-line maintenance therapy for this indication, signaling a key advancement in SCLC treatment.